Lista de obras - Ennio Giulio Favalli - Dominio Público Uruguay

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

artículo científico publicado en 2017

Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

artículo científico publicado en 2015

Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes

artículo científico publicado en 2008

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

scientific article published on 25 May 2020

Biomarkers in psoriatic arthritis: a systematic literature review

artículo científico publicado en 2016

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis

artículo científico publicado en 2018

Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting

artículo científico publicado en 2017

Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies

artículo científico publicado en 2014

Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study"

artículo científico publicado en 2018

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries

artículo científico publicado en 2017

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

artículo científico publicado en 2020

Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature

artículo científico publicado en 2011

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.

artículo científico

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

artículo científico publicado en 2002

Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

artículo científico publicado en 2014

Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study

scientific article published on 01 April 2010

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register

artículo científico publicado en 2014

Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.

artículo científico publicado en 2016

Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

artículo científico publicado en 2015

Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry

scientific article published on 07 February 2020

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.

artículo científico publicado en 2017

How advances in personalized medicine will change rheumatology

scientific article published on 02 February 2018

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

artículo científico publicado en 2020

Incidence of cancer in patients with spondyloarthritis treated with anti-tnf drugs

artículo científico publicado en 2017

Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

artículo científico publicado en 2020

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade

scholarly article by Francesca Ingegnoli et al published September 2008 in Journal of Autoimmunity

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphos

artículo científico publicado en 2017

Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry

artículo científico publicado en 2014

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry

artículo científico publicado en 2012

Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis

artículo científico publicado en 2019

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

artículo científico publicado en 2015

Novel mechanisms of action of the biologicals in rheumatic diseases.

artículo científico publicado en 2014

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

artículo científico publicado en 2013

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

scientific article published on 17 November 2009

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

artículo científico publicado en 2016

Predicting response to anti-TNF treatment in rheumatoid arthritis patients

artículo científico publicado en 2009

Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores

artículo científico publicado en 2013

Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.

artículo científico publicado en 2017

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

artículo científico publicado en 2017

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences

artículo científico publicado en 2017

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients

scientific article published on 19 June 2020

Sarilumab: patient-reported outcomes in rheumatoid arthritis

artículo científico publicado en 2018

Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

artículo científico publicado en 2008

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

artículo científico publicado en 2017

Structural integrity versus radiographic progression in rheumatoid arthritis

artículo científico publicado en 2015

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

artículo científico publicado en 2014

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

artículo científico publicado en 2015

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus

scholarly article by Monica Todoerti et al published 1 October 2018 in Rheumatology

Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry

scientific article published on 31 December 2009

TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

scientific article published on 01 September 2009

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects

artículo científico publicado en 2019

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides

scientific article published on 01 November 2014

The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting

artículo científico publicado en 2016

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors

artículo científico publicado en 2019

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives

artículo científico publicado en 2017

The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts

article

The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials

artículo científico publicado en 2012

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry

artículo científico publicado en 2018

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry.

artículo científico publicado en 2016

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection

article

Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs

artículo científico publicado en 2014

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

artículo científico publicado en 2008

Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry

scientific article published on 30 July 2009

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.

artículo científico publicado en 2015

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.

artículo científico publicado en 2017

Ultrasonography in the diagnosis and management of patients with inflammatory arthritides

artículo científico publicado en 2013

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis

artículo científico publicado en 2020

What is the true incidence of COVID-19 in patients with rheumatic diseases?

scientific article published on 22 April 2020

Lista de obras de Ennio Giulio Favalli

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.

Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

Biomarkers in psoriatic arthritis: a systematic literature review

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis

Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting

Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies

Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study"

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.

Drug-induced lupus following treatment with infliximab in rheumatoid arthritis.

Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register

Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.

Erratum to: Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis

Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.

How advances in personalized medicine will change rheumatology

Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Incidence of cancer in patients with spondyloarthritis treated with anti-tnf drugs

Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphos

Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry

Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

Novel mechanisms of action of the biologicals in rheumatic diseases.

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine

Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy

Predicting response to anti-TNF treatment in rheumatoid arthritis patients

Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores

Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences

Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients

Sarilumab: patient-reported outcomes in rheumatoid arthritis

Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

Structural integrity versus radiographic progression in rheumatoid arthritis

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies

Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus

Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry

TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides

The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting

The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors

The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives

The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts

The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials

The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry

The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry.

Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection

Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs

Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal

Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry

Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.

Ultrasonography in the diagnosis and management of patients with inflammatory arthritides

Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis

What is the true incidence of COVID-19 in patients with rheumatic diseases?